Information is given in tabular form de-
ciated disorders (table 1) , a pictorial representation of this information (fig la-d) , and an index of disorders for which the causative mutations have been mapped (table 2) .
In table 1, information on genes that have been located to specific chromosomal positions and are also the site of disease producing mutations is arranged by chromosome, starting with chromosome 1 and with the end of the short arm of the chromosome in each case.
In table 2 an alphabetised list of these disorders and the chromosomal location of the mutation in each case are provided. Both in the 'Disorder' field of table 1 and in table 2, the numbers 1, 2, or 3 in parentheses after the name of the disorder indicate that its chromosomal location was determined by mapping of the wildtype gene (1), by mapping of the clinical phenotype (2), or by both strategies (3). (J Med Genet 1993; 30:1-26) The fields in the listing by chromosome (table 1) are as follows: Location -that is, chromosomal site (p = short arm; q = long arm; numbers = band; ter = end). Symbol -The symbol approved by the Nomenclature Committee of the Human Gene Mapping Workshops and their successor organisation is given first; alternative symbols are included. Status -C = confirmed; P = provisional; L= 'in limbo' (that is, tentative or inconsistent). The 'in limbo' entries are not listed in fig 1. Title -name of gene locus.
MIM# -This is the number in McKusick's Mendelian Inheritance in Man, 10th ed (1992) and its continuously updated online version OMIM. (For historical reasons, the number may sometimes indicate location of the entry in the 'dominant catalogue' because the wildtype gene was characterised and mapped before the recessive disorder resulting from mutation at that site. The practice is to create only one entry in OMIM for each gene locus.)
Method of mapping A = in situ DNA-RNA or DNA-DNA annealing ('hybridisation'), for example, ribosomal RNA genes to acrocentric chromosomes; kappa light chain genes to chromosome 2. AAS = deductions from the amino acid sequence of proteins, for example, linkage of delta and beta globin loci from study of hemoglobin Lepore. C = chromosome mediated gene transfer (CMGT), for example, cotransfer of galactokinase and thymidine kinase. Ch = chromosomal change associated with particular phenotype and not proved to represent linkage (Fc), deletion (D), or virus effect (V), for example, loss of 13q14 band in some cases of retinoblastoma. D = deletion or dosage mapping (concurrence of chromosomal deletion and phenotypic evidence of hemizygosity), trisomy mapping (presence of three alleles in the case of a highly polymorphic locus), or gene dosage effects (correlation of trisomic state of part or all of a chromosome with 50% more gene product). Includes 'loss of heterozygosity' (loss of alleles) in malignancies. Examples: acid phosphatase-1 to chromosome 2; glutathione reductase to chromosome 8. Includes DNA dosage, for example, fibrinogen loci to 4q2. Dosage mapping also includes coamplification in tumour cells. EM= exclusion mapping, that is, narrowing the possible location of loci by exclusion of parts of the map by deletion mapping, extended to include negative lod scores from families with marker chromosomes and negative lod scores with other assigned loci, for example, support for assignment of MNSs to 4q. F = linkage study in families, for example, linkage of ABO blood group and nail-patella syndrome. (When a chromosomal heteromorphism or rearrangement is one trait, Fc is used, for example, Duffy blood group locus on chromosome 1. When one or both of the linked loci are identified by a DNA polymorphism, Fd is used, for example, Huntington's disease on chromosome 4. F = L in the HGM workshops.) H = based on presumed homology, for example, proposed assignment of TF to 3q. Mainly heuristic or confirmatory. HS = DNA/cDNA molecular hybridisation in solution ('Cot analysis'). L = lyonisation, for example, OTC to X chromosome. (L = symbol for family linkage study in the HGM workshops.) LD = linkage disequilibrium, for example, beta and delta globin genes. M = Microcell mediated gene transfer (MMGT), for example, a collagen gene (COLlAl) to chromosome 17. OT = ovarian teratoma (centromere mapping), for example, PGM3 and centromere of chromosome 6. Pcm = PCR of microdissected chromosome segments (see REI). Psh = PCR of somatic cell hybrid DNA. R = radiation hybrids, that is, irradiation of cells followed by 'rescue' through fusion with non-irradiated (non-human) cells (Goss-Harris method of radiation-induced gene segregation), for example, order of genes on Xq. RE= restriction endonuclease techniques, for example, fine structure map of the beta globin cluster (HBBC) on I lp; physical linkage of 3 fibrinogen genes (on 4q). REa = combined with somatic cell hybridisation, for example, NAG (HBBC) to lip. Allelic series as the basis of phenotypic diversity are well illustrated by Duchenne and Becker muscular dystrophies and by the several forms of spinal muscular atrophy. Gardner syndrome and adenomatous polyposis coli (without extra-bowel manifestations) are demonstrably allelic; indeed the fact that the same mutation has been shown to cause one or the other of these two disorders in different members of the same family indicates that the two syndromes represent variability of expression.
Mapping information suggests that some syndromes with a combination of manifestations may result from mutation in a complex locus, that is, the particular pattern of components may be determined by the part of the gene affected by the mutation. Von HippelLindau syndrome and multiple endocrine Fumarase deficiency (1) I l-beta-hydroxysteroid dehydrogenase deficiency (1) Thyroid iodine peroxidase deficiency (1) ACTH deficiency (1) Hypobetalipoproteinemia (1) (2) Cataract, Coppock-like (3) i(Cryg-1) Cerebrotendinous xanthomatosis 1(Cyp27) (2) Leukemia/lymphoma, T-cell (2) Acyl-CoA dehydrogenase, long chain, deficiency of (1) ?Ehlers-Danlos syndrome, type X 1 (Fn-1)
(1) ?Cardiomyopathy (1) I(Des) Waardenburg syndrome, type I (3) Crigler-Najjar syndrome, type I, l(Ugt-1) 218800 (1); ? (Gilbert syndrome, 143500) (1) (1) Oroticaciduria (1) 16(Pit-l,dw)
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